8.235USD+0.06%Mkt Cap: 1.80B USDP/E: —Last update: 2026-05-26
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation techno…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.80B USD
Enterprise Value1.21B USD
Revenue (TTM)52.04M USD
Gross Profit45.38M USD
Net Income (TTM)-265.94M USD
Revenue/Share0.2590 USD
Last Price8.235 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees325
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS67576A1007
Valuation
P/E (Trailing)—
P/E (Forward)-5.38
PEG—
EV/EBITDA-4.11
EV/Revenue23.30
P/S34.59
P/B2.71
EPS (TTM)-1.44
EPS (Forward)-1.53
52W Range
6.23020% of range16.44
52W High16.44 USD
52W Low6.230 USD
Profitability
Gross Margin87.35%
Oper. Margin-865.46%
EBITDA Margin0.00%
Profit Margin-511.90%
ROE-40.64%
ROA-32.91%
Growth
Revenue Growth0.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-204.88M USD
CapEx (TTM)12.01M USD
FCF Margin-285.87%
FCF Yield-8.25%
Net Debt-587.24M USD
Net Debt/EBITDA1.99
Balance Sheet
Debt/Equity0.12
Current Ratio14.81
Quick Ratio14.49
Book Value/Sh3.030 USD
Cash/Share3.045 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)26.00 USD
Target Range18.00 USD – 34.00 USD
# Analysts11
Ownership
Shares Out.218.96M
Float184.63M
Insiders0.87%
Institutions95.72%
Short Interest
Short Ratio7.5d
Short % Float13.37%
Short % Out.11.33%
Shares Short24.79M
Short (prev mo.)25.19M
Technical
SMA 508.855 (-7.0%)
SMA 20010.86 (-24.2%)
Beta0.93
S&P 52W Chg28.31%
Avg Vol (30d)2.87M
Avg Vol (10d)3.02M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—